UNSPSC 51111759: Piroxantrone

This classification denotes an anthrapyrazole antibiotic with the molecular formula C21H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YL4TY9WH22, chemically known as anthra(1,9-cd)pyrazol-6(2h)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)- but generally known as piroxantrone, which bears US NIH Compound Identifier 5362372. European Medicines Agency schedules Piroxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09935MIG.

UNSPSC 51111759 Piroxantrone, a Commodity code, shows limited recent state and local procurement activity aligned with its nominal pharmaceutical product scope. The two opportunities captured under this code do not reflect piroxantrone procurement; instead, they represent broader pharmaceutical and medical-supply purchasing by state health departments and county health authorities. The Illinois Department of Public Health awarded a $2,999,999.11 three-year piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), and Seminole County, Florida solicited annual purchases of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems through an IFB process. These acquisitions reflect state and local demand for emergency pharmaceuticals and harm-reduction supplies rather than chemotherapy agents such as piroxantrone. The issuing bodies are state health departments and county public-health agencies, which use cooperative purchasing vehicles and competitive bidding to acquire pharmaceutical inventories for distribution and community health initiatives.

Recent activity appears concentrated in Florida and Illinois, with the Seminole County procurement requiring quarterly deliveries to a designated county health facility and the Illinois award administered through a multi-state cooperative. The Seminole County IFB closed on July 26, 2023, with vendors responsible for all shipping costs and required to meet E-Verify, workers' compensation, and general liability insurance standards; the procurement included a three-month probationary termination clause and potential FEMA funding compliance obligations. The code shows no current open solicitations for piroxantrone or closely related chemotherapy agents under state and local notice systems; the opportunities recorded reflect tagging mismatches rather than active demand in this specific pharmaceutical category.